Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19514767 | 1.00 | LMNA (0.36) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL28352023 | 1.00 | LMNA (0.36) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL16634764 | 0.95 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL20603238 | 0.89 | PGD (0.33) | PGDPTPN1 | |
| SCHEMBL16038475 | 0.89 | PGD (0.33) | PGDPTPN1 | |
| SCHEMBL7076428 | 0.88 | PDE4A (0.32) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL37329 | 0.84 | PGD (0.36) | LMNAL3MBTL1PDE4APGD | |
| SCHEMBL4959396 | 0.84 | PGD (0.36) | LMNAL3MBTL1PDE4APGD | |
| SCHEMBL9736395 | 0.84 | PGD (0.36) | LMNAL3MBTL1PDE4APGD | |
| Fructose SCHEMBL769239 | 0.83 | PGD (0.34) | PDE4APGDCYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4627351-A1 | METHODS FOR DETECTING METABOLIC MARKERS | Cedars-Sinai Medical Center (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250283891-A1 | METHODS FOR DETECTING METABOLIC MARKERS | CEDARS SINAI MEDICAL CENTER (US) | 2025-09-11 | — | — | US | disclosed |
| CN-118525097-A | Novel promoter variants for constitutive expression and uses thereof | 大象株式会社 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024118850-A1 | METHODS FOR DETECTING METABOLIC MARKERS | CEDARS-SINAI MEDICAL CENTER (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-117016703-A | Lipid-lowering antioxidant fruit and vegetable beverage and preparation method thereof | 杭州天曲生物技术有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20220071880-A1 | METHODS FOR TREATING CUTANEOUS AGING | Applied Therapeutics, Inc. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3924060-A1 | METHODS FOR TREATING CUTANEOUS AGING | Applied Therapeutics Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167937-A1 | METHODS FOR TREATING CUTANEOUS AGING | Applied Therapeutics, Inc. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-1021175-B1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CT (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-1311847-B1 | Quantitative analysis of hexose-monophosphates from biological samples | STATENS SERUMINSTITUT (DK) | 2015-01-14 | — | — | EP | disclosed |
| EP-1126856-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1085885-A2 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CENTER (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000024405-A9 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-10-19 | — | — | WO | disclosed |
| EP-1021175-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000024405-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-05-04 | — | — | WO | disclosed |
| US-6004958-A | ADMINISTERING FRUCTOSE-LYSINE-3-PHOSPHATE KINASE INHIBITOR; INHIBITING DEOXYGLUCOSONE BY-PRODUCT FORMATION | FOX CHASE CANCER CENTER (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1999064561-A2 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CENTER (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998033492-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5231031-A | Metabolites | FOX CHASE CANCER CENTER (US) | 1993-07-27 | — | — | US | disclosed |
| US-5231031-A | Metabolites | FOX CHASE CANCER CENTER (US) | 1993-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071880-A1 | METHODS FOR TREATING CUTANEOUS AGING | GLA, ADH1B, ALDH2 | LMNA 1138/4885L3MBTL1 3548/4885PDE4A 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.